drugset / Trial / NCT01264874

MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients

NCT01264874

Phase 3 Terminated 150 enrolled European Institute of Oncology
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to assess the effect of vitamin D supplementation on recurrence in resected stage II melanoma patients.

Timeline

Start
2010-05
Primary completion
2017-07
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 100000 iu

Indications